Midomafetamine
- Generic Name
- Midomafetamine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H15NO2
- CAS Number
- 42542-10-9
- Unique Ingredient Identifier
- KE1SEN21RM
- Background
An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.
- Indication
Clinical trials are now testing the therapeutic potential of MDMA for post-traumatic stress disorder (PTSD) and anxiety associated with terminal cancer. MDMA is one of the four most widely used illicit drugs in the U.S.
- Associated Conditions
- -
- Associated Therapies
- -
Lykos CEO to Resign After FDA Rejection of MDMA Therapy, Layoffs
Lykos Therapeutics CEO Amy Emerson steps down, interim CEO Michael Mullette appointed. Emerson to remain as senior advisor. Lykos faces FDA rejection for MDMA therapy, plans resubmission. Company also names David Hough as CMO and lays off 75% of workforce.
Lykos CEO to depart after FDA rejection, layoffs
Lykos Therapeutics CEO Amy Emerson to step down after FDA rejection of MDMA therapy aid approval. Michael Mullette appointed interim CEO. Company plans to cut 75% of workforce and resubmit MDMA approval application.
'Tofu-Like' Psychedelic Gets FDA Nod - Mindstate's AI-Designed Therapy To Begin Human Trials
Mindstate Design Labs received FDA and EMA approval for human trials of MSD-001, described as 'psychedelic tofu' for its mild effects. The trials aim to validate the neurotech AI platform, Osmanthus, designed to create tailored altered states of consciousness. CEO Dillan DiNardo envisions using psychedelics as tools to understand and design specific mental states, potentially addressing conditions beyond traditional psychedelic uses.
Emyria announces interim clinical trial results for PTSD program
Emyria reports interim clinical results from its MDMA-assisted therapy for PTSD, showing improved outcomes for eight patients with moderate to severe PTSD. The program aims to recruit 70 patients.
Recreational Drug Use Triples Odds for Repeat Heart Crises
Recreational drug use triples the risk of repeat heart crises within a year, with MDMA users four times more likely, according to a study by Dr. Raphael Mirailles.
Lykos Therapeutics Announces Complete Response Letter for Midomafetamine Capsules for PTSD
Lykos Therapeutics received a complete response letter from the FDA for midomafetamine capsules for PTSD, requesting an additional Phase 3 trial. The company plans to meet with the FDA to discuss resubmission and address concerns raised during the Advisory Committee meeting.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath